Are There Any Biomarkers for Predicting Immunotherapy Response?
Yes, several biomarkers can predict how well a patient might respond to immunotherapy:
PD-L1 Expression: Higher levels of PD-L1 on tumor cells can indicate a better response to PD-1/PD-L1 inhibitors. Tumor Mutational Burden (TMB): A high TMB means more mutations, potentially leading to more neoantigens that the immune system can target. Microsatellite Instability (MSI): Tumors with high MSI are more likely to respond to immune checkpoint inhibitors.
